Brown, PhD, DSc, FRSC, 19382016: Discoverer of GIP and Motilin', Gastroenterology , 153/6, 1169-71
For instance, semaglutide has been approved and is being researched for indications including obesity, T2DM, reducing cardiovascular risk, chronic kidney disease, NAFLD, and AD, indicating that the development of new indications could provide new growth opportunities for GLP-1 drugs
Nevertheless, treatment of diabetes was obviously of great interest, but how to do it
GLP-1 patches are OTC (over-the-counter) transdermal patches that claim to deliver GLP-1 drugs through the skin
It also claims that it aids in healthy weight management
As semaglutide users lose weight, their bodies require less cholesterol production, naturally lowering blood levels